Eligibility for the Medicare GLP-1 Bridge will also be limited to Medicare beneficiaries who have not filled a prescription under their Part D plan for a GLP-1 in 2026, and who do not have a diagnosis with a condition that is a medically accepted indication for a GLP-1 drug that could be covered under Part D (specified by CMS as type 2 diabetes, obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)), even if they otherwise meet the clinical criteria
A telehealth intake form that does not specifically ask about MEN2 or MTC family history, or that relies on a patient correctly self-identifying those diagnoses, is a gap that in-person endocrinology care closes more reliably
Data suggested that fisetin may be a suitable therapeutic candidate for aging and neurological diseases
Recent findings suggest that a protective role of Nrf2 on oxidative stress in aging (de Oliveira et al., 2018)
The small numbers problem Clinical trials capture rare events in controlled settings
In an experimental study conducted in rats treated with therapeutic and toxic doses of VPA, Shakoor [63] found that carnitine supplementation was able to prevent fatty infiltration and liver necrosis induced by VPA